MGX insider files Form 144 to sell 35,832 shares via Merrill Lynch

Rhea-AI Filing Summary

Metagenomi, Inc. filed a Form 144 notifying a proposed sale of 35,832 common shares through Merrill Lynch on 09/11/2025 on the NASDAQ, with an aggregate market value of $68,080.80. The filing shows the shares were acquired as stock awards from Sarah Noonberg: 26,631 shares on 01/30/2003 and 9,201 shares on 06/05/2025, with payment listed as cash. The issuer has 37,533,136 shares outstanding. The filer reports no sales of the issuer's securities in the past three months and includes the standard signer representation that no undisclosed material adverse information exists.

Positive

• Complete disclosure of number of shares, acquisition dates, broker, and aggregate market value
• No reported sales in the past three months, indicating this is a discrete, scheduled sale
• Securities provenance listed (stock awards from Sarah Noonberg) and payment method (cash) are specified

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for an insider stock award sale; disclosure is specific with acquisition dates and broker details.

The filing documents a proposed sale of 35,832 common shares via Merrill Lynch with clear acquisition history and cash payment notation. The inclusion of the number of shares outstanding (37,533,136) allows investors to gauge the sale's relative size (approximately 0.095% of outstanding shares). The filing also states no sales in the past three months, which supports the view that this is a scheduled disposition rather than an ongoing trading pattern. As a Form 144, it serves primarily as regulatory transparency rather than a material corporate event.

Corporate Governance Expert

TL;DR: The notice is a standard insider sale disclosure with explicit provenance of shares and use of a registered broker.

The form identifies the shares as stock awards from a named individual and specifies Merrill Lynch as the executing broker, which aligns with common governance and compliance practices for insider dispositions. The filer reiterates the standard attestation about absence of undisclosed material adverse information. No other governance actions, leadership changes, or related-party transactions are disclosed in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 555 CALIFORNIA STREET 9TH FLOOR SAN FRANCISCO CA 94104	35832	68080.80	37533136	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/30/2003	STOCK AWARD	SARAH NOONBERG			26631	01/30/2003	CASH
COMMON	06/05/2025	STOCK AWARD	SARAH NOONBERG			9201	06/05/2025	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Metagenomi (MGX) Form 144 notify?

The Form 144 notifies a proposed sale of 35,832 common shares to be executed through Merrill Lynch on 09/11/2025 on the NASDAQ.

What is the aggregate market value and outstanding shares reported?

The aggregate market value is reported as $68,080.80 and the number of shares outstanding is 37,533,136.

When and how were the shares acquired?

Shares were acquired as stock awards from Sarah Noonberg: 26,631 on 01/30/2003 and 9,201 on 06/05/2025, with payment listed as cash.

Were any shares of the issuer sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Which broker is handling the sale?

The sale is listed with Merrill Lynch, address: 555 California Street 9th Floor, San Francisco, CA 94104.